Scholarlink

<p>This study explored the presence of bioactive compounds in the methanolic extract of Elephant foot yam (EFY) and also evaluated its antidiabetic efficacy. These compounds include sitoindoside-II, β-sitosterol β-<span>d</span>-glucopyranoside, catechin, and kaempferol 3-<i>O</i>-glucoside. Uncontrolled and unintentional weight loss is common in individuals with diabetes. Administration of the EFY methanolic extract to streptozotocin-induced diabetic rats resulted in a significant reduction in weight loss, from 11% to 2-3%. The high-dose methanolic extract administered group exhibited a significant reduction in fasting blood glucose (FBG) levels by the sixth week (from 553 to 304&#xa0;mg/dL) and improved oral glucose tolerance test (OGTT area under curve (AUC): 58,375 ± 2095&#xa0;mg/dL) compared with the diabetic control group (FBG: 557 to 505&#xa0;mg/dL, OGTT AUC: 75,410 ± 1925&#xa0;mg/dL). Tubers are often not included in the diet of diabetic individuals; however, considering the presence of bioactive compounds and the positive effects observed in preclinical studies, EFY may be included in the diet of diabetic individuals while maintaining appropriate portion sizes.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Phytochemical characterization and antidiabetic efficacy of elephant foot yam (Amorphophallus paeoniifolius) extract in a high-fat diet and low-dose streptozotocin-induced diabetic rat model

  • 期刊论文

  • 发表日期：

    2026年3月26日

查看全文
  • Gopika Biju,
  • Nagaraja Ingaladal,
  • Sruthi P. K.,
  • Achuthan C. Ragavamenon,
  • Ravi S. Lankalapalli,
  • M. V. Reshma

摘要

This study explored the presence of bioactive compounds in the methanolic extract of Elephant foot yam (EFY) and also evaluated its antidiabetic efficacy. These compounds include sitoindoside-II, β-sitosterol β-d-glucopyranoside, catechin, and kaempferol 3-O-glucoside. Uncontrolled and unintentional weight loss is common in individuals with diabetes. Administration of the EFY methanolic extract to streptozotocin-induced diabetic rats resulted in a significant reduction in weight loss, from 11% to 2-3%. The high-dose methanolic extract administered group exhibited a significant reduction in fasting blood glucose (FBG) levels by the sixth week (from 553 to 304 mg/dL) and improved oral glucose tolerance test (OGTT area under curve (AUC): 58,375 ± 2095 mg/dL) compared with the diabetic control group (FBG: 557 to 505 mg/dL, OGTT AUC: 75,410 ± 1925 mg/dL). Tubers are often not included in the diet of diabetic individuals; however, considering the presence of bioactive compounds and the positive effects observed in preclinical studies, EFY may be included in the diet of diabetic individuals while maintaining appropriate portion sizes.